These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31262190)

  • 1. LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis.
    Ge Q; Zhao L; Ren XM; Ye P; Hu ZY
    Exp Biol Med (Maywood); 2019 Sep; 244(12):1028-1039. PubMed ID: 31262190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
    Suematsu Y; Miura S; Goto M; Matsuo Y; Arimura T; Kuwano T; Imaizumi S; Iwata A; Yahiro E; Saku K
    Eur J Heart Fail; 2016 Apr; 18(4):386-93. PubMed ID: 26749570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
    Kusaka H; Sueta D; Koibuchi N; Hasegawa Y; Nakagawa T; Lin B; Ogawa H; Kim-Mitsuyama S
    Am J Hypertens; 2015 Dec; 28(12):1409-17. PubMed ID: 25762811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats.
    Alqahtani F; Mohany M; Alasmari AF; Alanazi AZ; Belali OM; Ahmed MM; Al-Rejaie SS
    Int J Med Sci; 2020; 17(18):3098-3106. PubMed ID: 33173431
    [No Abstract]   [Full Text] [Related]  

  • 5. Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage.
    Bai HY; Mogi M; Nakaoka H; Kan-No H; Tsukuda K; Chisaka T; Wang XL; Kukida M; Shan BS; Yamauchi T; Higaki A; Iwanami J; Horiuchi M
    Eur J Pharmacol; 2015 Sep; 762():293-8. PubMed ID: 26057694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy.
    Malek V; Gaikwad AB
    Cardiovasc Res; 2019 Feb; 115(2):373-384. PubMed ID: 30184174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Ameliorates Endothelial Dysfunction in Diabetic C57BL/6 Mice.
    Munkhjargal U; Fukuda D; Maeda J; Hara T; Okamoto S; Bavuu O; Yamamoto T; Sata M
    J Atheroscler Thromb; 2024 Sep; 31(9):1333-1340. PubMed ID: 38616113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LCZ696 Protects against Diabetic Cardiomyopathy-Induced Myocardial Inflammation, ER Stress, and Apoptosis through Inhibiting AGEs/NF-κB and PERK/CHOP Signaling Pathways.
    Belali OM; Ahmed MM; Mohany M; Belali TM; Alotaibi MM; Al-Hoshani A; Al-Rejaie SS
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice.
    Ge Q; Zhao L; Liu C; Ren X; Yu YH; Pan C; Hu Z
    Biomed Res Int; 2020; 2020():7256862. PubMed ID: 32420365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
    Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
    Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LCZ696 (sacubitril/valsartan) protects against cyclophosphamide-induced testicular toxicity in rats: Role of neprilysin inhibition and lncRNA TUG1 in ameliorating apoptosis.
    Salama RM; Abd Elwahab AH; Abd-Elgalil MM; Elmongy NF; Schaalan MF
    Toxicology; 2020 May; 437():152439. PubMed ID: 32197949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy.
    Xia Y; Chen Z; Chen A; Fu M; Dong Z; Hu K; Yang X; Zou Y; Sun A; Qian J; Ge J
    J Mol Cell Cardiol; 2017 Jul; 108():138-148. PubMed ID: 28623750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SIRT6‑specific inhibitor OSS‑128167 exacerbates diabetic cardiomyopathy by aggravating inflammation and oxidative stress.
    Huang Y; Zhang J; Xu D; Peng Y; Jin Y; Zhang L
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
    Gori M; Volterrani M; Piepoli M; Senni M
    Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.
    Hua Y; Wang I; Liu B; Kelly DJ; Reid C; Liew D; Zhou Y; Wang BH
    Future Cardiol; 2017 Mar; 13(2):103-115. PubMed ID: 27892684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
    Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
    von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
    Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats.
    Yu W; Wu J; Cai F; Xiang J; Zha W; Fan D; Guo S; Ming Z; Liu C
    PLoS One; 2012; 7(12):e52013. PubMed ID: 23251674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress.
    Sorrentino A; Steinhorn B; Troncone L; Saravi SSS; Badole S; Eroglu E; Kijewski MF; Divakaran S; Di Carli M; Michel T
    Am J Physiol Heart Circ Physiol; 2019 Sep; 317(3):H617-H626. PubMed ID: 31298558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
    Barghash MH; Desai AS
    Clin Pharmacol Ther; 2017 Aug; 102(2):265-268. PubMed ID: 28512738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.